Keith Fargo, PhD
Keith N. Fargo, Ph.D., is director of Scientific Programs & Outreach at the Alzheimer’s Association. He leads research programs and initiatives to accelerate the Association’s vision of a world without Alzheimer’s and all other dementia.
A key member of the Scientific Engagement team, Dr. Fargo works with all 75 Association chapters, media and donors to grow understanding of the Association’s role in accelerating Alzheimer’s research and share scientific updates. He is responsible for overseeing the data reported in the Association’s annual Alzheimer’s Disease Facts and Figures, the definitive compilation of national statistics and information conveying the impact of Alzheimer's and other dementias on individuals, families, government and the nation's health care system.
Dr. Fargo directs the Association’s efforts to build participation in Alzheimer’s disease research studies as a critical component of advancement in the field. He manages the Association’s role in recruiting participants for the Longitudinal Early-Onset Alzheimer’s Disease Study (LEADS), the world’s largest study of early-onset Alzheimer’s disease and how it compares to the more common late-onset Alzheimer’s disease. Dr. Fargo also ensures the quality, responsiveness and promotion of Alzheimer’s Association TrialMatch®, a free clinical studies matching service that connects individuals with Alzheimer's, caregivers and healthy volunteers to hundreds of current studies.
As an Association spokesperson, Dr. Fargo addresses emerging Alzheimer’s disease research and has been quoted in a variety of outlets, including ABCNews.go.com, CNNnews.com, TIME magazine and Wired magazine.
Dr. Fargo received his Ph.D. from Indiana University and completed a postdoctoral fellowship at Loyola University Stritch School of Medicine. Before joining the Alzheimer’s Association, Dr. Fargo held positions as a research scientist at the Edward Hines, Jr. VA Hospital Rehabilitation Research & Development Program and an assistant research professor at the Loyola University Chicago Department of Molecular Pharmacology & Therapeutics.